ZHEJIANG LEPU PHARMACEUTICAL CO.,LTD was founded in 2001. It is located in Jiaojiang block, Chemical API Industrial Park, Taizhou, Zhejiang. The company covers an area of nearly 300 mu, and is mainly engaged in the research and development, production and sales of anti-infection, anti-tumor, cardiovascular and nervous system, and other series of drugs. The company follows the development strategy of association between strong enterprises. In 2012, the company introduced Zhejiang Materials Industry Group, the Fortun 500, as a new shareholder. In 2014, the company introduced Lepu Medical Technology (Beijing) Co., Ltd. as the controlling shareholder, and integrated into a main pharmaceutical company that engages in apparatus, pharmacy, service and mobile medical in the cardiovascular whole industry chain platform under Lepu Medical Technology (Beijing) Co., Ltd. The leading products are norfloxacin, atorvastatin, rosuvastatin, sertraline hydrochloride and other API and preparations. The company attaches great importance to product quality, and has passed the GMP certification and registration of CFDA in China ,FDA in USA , MHRA in UK, COS in EU, PMDA in Japan, KFDA in South Korea etc. Many products have occupied a leading position in the world.
The company is a high-tech enterprise and provincial patent demonstration enterprise, and has a provincial research institute and provincial academician workstation. The company once set up the PhD stipend in the Department of Chemistry and Department of Chemical Engineering in Tsinghua University, Peking University, Zhejiang University, USTC, Nankai University and other famous universities, and jointly built laboratory with SIPI and SIIA and other domestic famous universities and research institutes. The company hired a group of professors and industry experts as the research and development instructor, and set up a bridge between industrial capital and intellectual capital. In recent years, the company has enhanced the research and development of new products and the protection of intellectual property rights, and has obtained more than 20 patents. At present, the company has extensive cooperation with more than 20 international companies, and is speeding up the research and development of cardiovascular, anti-tumor and other new drugs, which provides lasting power for medium and long-term development.
Looking to the future, the company will be adhering to the core values of “Seeking truth, innovation, integrity, win-win” and the enterprise spirit of “Dedication to the work, law-abiding, contribution”,Work diligently and be explorative and innovative. The company follows the medical industry policies to enhance technological innovation and accelerate the transformation and upgrading. Through the adjustment of product structure, extend the industrial chain, improve equipment, be strong in API manufacturing and be excellent in finished drug products manufacturing. Improve the core competitiveness of the enterprise, and strive to create a modern pharmaceutical enterprise with international competitiveness..